Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is exhibiting promising outcomes in preliminary human studies. Recent inquiry implies that https://infopagex.com/story6799942/retatrutide-emerging-studies-and-possible-therapeutic-applications